Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows

Abstract

Nonalcoholic steatohepatitis (NASH) with liver fibrosis is an increasingly important cause of liver-related morbidity and mortality. A diagnosis of NASH can only be made using liver biopsy. Liver histology also forms the endpoint for the expedited licensing strategies that have been approved by regulators to allow patients with NASH access to treatment before the impact of these on clinical outcomes is known. Validation of these histological surrogate endpoints is critical for the ongoing development of new therapies for NASH. The use of liver biopsy to define both trial entry and endpoints raises questions about the use of treatments for NASH in practice when the effectiveness of treatment will likely depend, at least in part, on the use of histology for patient selection in the real world.

Keywords

NASH - NAFLD - surrogate - validity

Publication History

Article published online:
09 September 2020

• References

• 1 Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017; 377 (21) 2063-2072
• 2 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (01) 73-84
• 3 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24 (07) 908-922
• 4 Younossi ZM, Loomba R, Anstee QM. et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018; 68 (01) 349-360
• 5 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67 (01) 328-357
• 6 Kleiner DE, Brunt EM, Van Natta M. et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (06) 1313-1321
• 7 Bedossa P. FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60 (02) 565-575
• 8 Pais R, Charlotte F, Fedchuk L. et al; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59 (03) 550-556
• 9 McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62 (05) 1148-1155
• 10 Filozof C, Chow SC, Dimick-Santos L. et al. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic. Hepatol Commun 2017; 1 (07) 577-585
• 11 Cheung A, Neuschwander-Tetri BA, Kleiner DE. et al; Liver Forum Case Definitions Working Group. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum. Hepatology 2019; 70 (05) 1841-1855
• 12 Administration FaD. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. Available at: https://www.fda.gov/media/119044/download . Published 2018. Accessed November 23, 2019
• 13 Administration FaD. Nonalcoholic steatohepatitis with compensated cirrhosis: developing drugs for treatment. Available at: https://www.fda.gov/media/127738/download . Published 2019. Accessed November 23, 2019
• 14 Hagström H, Nasr P, Ekstedt M. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017; 67 (06) 1265-1273
• 15 Younossi ZM, Stepanova M, Rafiq N. et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53 (06) 1874-1882
• 16 Kleiner DE, Brunt EM, Wilson LA. et al; Nonalcoholic Steatohepatitis Clinical Research Network. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open 2019; 2 (10) e1912565
• 17 Angulo P, Kleiner DE, Dam-Larsen S. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149 (02) 389.e10-397.e10
• 18 Dulai PS, Singh S, Patel J. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017; 65 (05) 1557-1565
• 19 Manns MP, Buti M, Gane E. et al. Hepatitis C virus infection. Nat Rev Dis Primers 2017; 3: 17006
• 20 Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov 2007; 6 (12) 991-1000
• 21 van der Meer AJ, Veldt BJ, Feld JJ. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24) 2584-2593
• 22 Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2018; 68 (01) 25-32
• 23 Siddiqui MS, Harrison SA, Abdelmalek MF. et al; Liver Forum Case Definitions Working Group. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 2018; 67 (05) 2001-2012
• 24 Roskilly A, Shearer J, Parker R, Rowe IA. High rates of ineligibility for participation in trials of new therapies in non-alcoholic steatohepatitis: a systematic review. Eur J Gastroenterol Hepatol 2020; [epub ahead of print]
• 25 Parker R, Hodson J, Rowe IAC. Systematic review: current evidence in non-alcoholic fatty liver disease lacks relevance to patients with advanced fibrosis. J Gastroenterol Hepatol 2017; 32 (05) 950-956
• 26 Rinella ME, Tacke F, Sanyal AJ, Anstee QM. participants of the AASLD/EASL Workshop. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology 2019; 70 (04) 1424-1436
• 27 Kleiner DE, Bedossa P. Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists. Gastroenterology 2015; 149 (06) 1305-1308
• 28 Younossi ZM, Ratziu V, Loomba R. et al; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019; 394 (10215): 2184-2196
• 29 Younossi ZM, Ratziu V, Sanyal AJ. et al. Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis. Am J Gastroenterol 2016; 111: S1273
• 30 Han MAT, Altayar O, Hamdeh S. et al. Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019; 17 (04) 616-629.e26
• 31 Rinella ME, Tacke F, Sanyal AJ, Anstee QM. participants of the AASLD/EASL Workshop. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol 2019; 71 (04) 823-833
• 32 Downing A, Morris EJ, Corrigan N. et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut 2017; 66 (01) 89-96
• 33 Selby P. The impact of the process of clinical research on health service outcomes. Ann Oncol 2011; 22 (Suppl. 07) vii2-vii4
• 34 Look ARG. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring) 2014; 22 (01) 5-13
• 35 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149 (02) 367.e5-378.e5 , quiz e14–e15
• 36 Pavlides M, Birks J, Fryer E. et al. Interobserver variability in histologic evaluation of liver fibrosis using categorical and quantitative scores. Am J Clin Pathol 2017; 147 (04) 364-369
• 37 Ratziu V, Charlotte F, Heurtier A. et al; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128 (07) 1898-1906
• 38 Vuppalanchi R, Unalp A, Van Natta ML. et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7 (04) 481-486
• 39 Merriman RB, Ferrell LD, Patti MG. et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44 (04) 874-880
• 40 Rowe IA. The devotion to surrogate outcomes in drug development for liver disease. Nat Rev Gastroenterol Hepatol 2018; 15 (01) 1-2
• 41 Harrison SA, Abdelmalek MF, Caldwell S. et al; GS-US-321-0105 and GS-US-321-0106 Investigators. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 2018; 155 (04) 1140-1153
• 42 Ratziu V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials. J Hepatol 2018; 68 (02) 353-361
• 43 Friedman SL, Ratziu V, Harrison SA. et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 2018; 67 (05) 1754-1767